BIOTECH FRACTIONAL CFO
Strategic CFO Support for Scaling Biotech Companies
Boston-based fractional and interim CFO for early-stage biotech companies in the US and Europe. I put in the systems, processes, controls and team, then take you through financings and transactions to closing.
Transactions closed as CFO: Euronext RTO · $87M sale to Calliditas · $135M Nasdaq SPAC

CFO roles & engagements





Enodia and enGene engagements delivered through Danforth Advisors
Earlier finance roles

BIOTECH FRACTIONAL CFO
I build the finance function biotech companies need to scale
I'm a CFO with 25 years in finance across the US and Europe. I trained in audit at KPMG Paris and held finance roles at Alexion and Novartis before moving into biotech leadership.
As CFO of Genkyotex in Geneva (2012–2021), I led finance and every function outside R&D for nine years. I closed the company's private financings, executed its reverse takeover onto Euronext, served as public-company CFO for four years, and led the closing of its $87M sale to Calliditas through to delisting.
Since 2022, through Grassin Consulting, I've been fractional and interim CFO to biotech companies including HiFiBiO Therapeutics, Enodia Therapeutics and enGene: building finance functions, restructuring cost bases, and supporting financings and transactions.
Selected closings
Transactions I worked on as CFO, through to closing.
Euronext Paris & Brussels
Genkyotex’s stock-market listing through a reverse merger with Genticel.
CFO, Genkyotex · Ran the closing
Sale to Calliditas Therapeutics
Sale of Genkyotex, followed by the tender offer and delisting.
CFO, Genkyotex · Ran the closing
Nasdaq SPAC combination
enGene’s business combination with Forbion European Acquisition Corp.
Interim CFO, enGene, during the transaction